FDA approves treatment for paediatric patients with type 2 diabetes mellitus


22 July 2021 - The U.S. FDA today approved Bydureon and Bydureon BCise (exenatide extended release) injection to be used in addition to diet and exercise to improve glycemic control in paediatric patients 10 years or older with type 2 diabetes. 

Exenatide extended-release was previously approved to treat adults with type 2 diabetes mellitus.

Read FDA News

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Paediatrics , Disease